Boehringer Ingelheim's innovative non-catalytic site integrase inhibitors (NCINIs) for HIV have been granted exclusive worldwide rights to Gilead Sciences.

The lead compound BI 224436 from Boehringer Ingelheim, which was recently tested in a Phase 1a dose-escalation study, is included in the agreement.

NCINIs inhibit HIV 1 Integrase Drugs Development market by binding to a novel site and targeting the virus component that is responsible for the incorporation of viral DNA into the human genome.

Boehringer will be compensated in accordance with the terms of the agreement for an initial payment as well as the possibility of additional milestone payments in response to advancements in commercial, regulatory, and development

For additional bits of knowledge on the HIV 1 Integrase Drugs Development market, Download a FREE example